Pharma

Taking stock of the drug industry, from the lab to the medicine chest

Pharmalot

Pharmalittle: Sanofi weighs airlifting flu vaccine post-Brexit; speedy China OK for Roche cancer drug

By Elizabeth Cooney

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Trump wants opioid makers to cut production quotas; Purdue looks to restructure

By Ed Silverman

Alex Azar Part B
Pharmalot

Senators challenge Azar over his comments about PBMs and price cuts

By Ed Silverman

CHINA flag
Pharmalot

China takes action against numerous officials for allowing vaccine scandal to erupt

By Ed Silverman

Vertex
Pharmalot

An 8-year-old boy puts Vertex on the defensive over the price of its drugs in the U.K.

By Ed Silverman

Pfizer
Pharmalot

Pfizer resumes full production at a troubled plant, but don’t expect shortages to suddenly end

By Ed Silverman

Pill Dollars
Pharmalot

Never mind the rebates. Maybe behind-the-scenes fees are boosting drug prices

By Ed Silverman

Pharmalot

Pharmalittle: EpiPen shortage may cause back-to-school crisis; Mylan kept mum about a half-million dollar deal

By Ed Silverman

Gilead
Pharmalot

As Gilead plans a C-suite succession, the rash of top-level departures continues

By Ed Silverman

Pharmalot

Pharmalittle: More turnover at Gilead Sciences; EMA scales back its transparency policy

By Ed Silverman

ACT UP 1989
Health

As Alzheimer’s drug developers give up on today’s patients, where is the outrage?

By Sharon Begley

Pharmalot

CVS sets a cost-effectiveness threshold for health plan coverage of most new drugs

By Ed Silverman

CVS/Aetna
Pharmalot

Ohio Medicaid cancels contracts with two big PBMs over ‘spread’ pricing

By Ed Silverman

Charlie Baker
Pharmalot

To lower state drug costs, the National Governors Association is promoting several ideas

By Ed Silverman

Pharmalot

Pharmalittle: U.K. watchdog calls Biogen rare disease drug too pricey; Novartis hires a new ethics officer

By Ed Silverman

Pharmalot

Gilead patent for its hepatitis C drug is invalidated by Chinese authorities

By Ed Silverman

Pharmalot

Pharmalittle: Icahn dealt setbacks in bid to derail Cigna deal for Express Scripts; Pfizer suit against J&J proceeds

By Ed Silverman

Empty pipeline
Pharma

That pathetic Alzheimer’s pipeline? It’s even worse than you think

By Sharon Begley

FDA; Drug Administration campus
Pharmalot

FDA found problems at Chinese ingredients maker nearly two years before valsartan recalls

By Ed Silverman

Alex Gorsky
The Pharmalot View

From zero to hero: J&J CEO praises Trump one year after chastising him

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FDA approved record number of generics in July; feds join suits against Suboxone maker

By Ed Silverman

Vertex Pharmaceuticals Inc. building
Pharmalot

In clash over pricing, Vertex won’t give U.K. data needed to review a new cystic fibrosis drug

By Ed Silverman

India Tuberculosis Villages
Pharmalot

Lawmakers urge Trump to ensure access to TB drugs as UN meeting nears

By Ed Silverman

Pharmalot

Pharmalittle: Mylan is evaluating its options; GW will charge $32,500 for its cannabinoid for epilepsy

By Ed Silverman

Hepatitis C
Pharmalot

Louisiana explores a ‘Netflix’ subscription model for buying hepatitis C drugs

By Ed Silverman

John Kapoor
Pharmalot

Insys agrees to pay $150 million to settle federal probe into opioid marketing

By Ed Silverman

Injectable drugs
Pharmalot

Trump plan to give private Medicare leverage over drug costs would boost PBMs and biosimilars

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy